Resistance may not be futile: MicroRNA biomarkers for chemoresistance and potential therapeutics

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3126-3136

  Allen, Kristi E ^a   Weiss, Glen J ^a,b  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b HonorHealth Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAK1; PROTEIN PDCD4; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER MORTALITY; CANCER RESISTANCE; CANCER THERAPY; GENE CONTROL; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 78650491562     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0397     Document Type: Review

References (62)

1. American Cancer Society. Cancer facts & figures 2009. Atlanta: American Cancer Society; 2009.
2. Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010;13(3):57-66.
3. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
4. Zheng T, Want J, Chen S, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer 2009;126(1):2-10.
5. Lui FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy - a quick review. Taiwan J Obstet Gynecol 2009;48(3):239-44.
6. Wu X, Xiao H. miRNAs modulate the drug response of tumor cells. Sci China C Life Sci 2009;9:797-801.
7. Zhang X, Yashiro M, Qiu H, Nishii T, Matsuzaki T, Hirakawa K. Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res 2010;30(3):915-21.
8. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265-83.
9. Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010;12(8):628-36.
10. Li J, Li ZN, Du YJ, Li XQ, Bao QL, Chen P. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: Correlation with response to chemotherapy and survival. Clin Lung Cancer 2009;10(6):414-21.
11. Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatinbased chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 2010;213(2):140-5.
12. Osawa K. Gene polymorphisms and chemotherapy in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2009;12(8):837-40.
13. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dehydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-7.
14. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Kashiwaba M, et al. Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by realtime RT-PCR. Jpn J Cancer Res 2002;93:1342-50.
15. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. (published online ahead of print September 1, 2010). Breast Cancer Res Treat.
16. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 2008;9(2):102-14.
17. Bartel DP. microRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97.
18. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: Tools for microRNA genomics. NAR 2008;36(Database Issue):D154-58.
19. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: MicroRNA sequences, targets and gene nomenclature. NAR 2006;34(Database Issue):D140-44.
20. Griffiths-Jones S. The microRNA Registry. NAR 2004;32(Database Issue):D109-11.
21. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455(7209):58-63.
22. Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, et al. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene 2010;29(15):2302-8.
23. Calin GA, Croce CM. microRNA signatures in human cancers. Nat Rev Cancer 2006;6(11):857-66.
24. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. microRNA expression profiles classify human cancers. Nature 2005;435(7043):834- 8.
25. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101(9):2999-3004.
26. Caldas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med 2005;11(7):712-4.
27. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006;103(24):9136-41.
28. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007;39(5):673-7.
29. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004;305(5689):1437-41.
30. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 2004;15(2):185-97.
31. Ferracin M, Veronese A, Negrini M. Micromarkers: MiRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010;10(3):297-308.
32. Chen X, Ba Y, Ligia M. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18(10):997-1006.
33. Ranade AR, Cherba D, Shridhar S, Richardson P, Webb C, Paripati A, et al. microRNA 92a-2.: A biomarker predictive for chemoresistance and prognostic for survival in small cell lung cancer patients. J Thorac Oncol 2010;5(8):1273-8.
34. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009;28(46):4065-74.
35. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010;9(96).
36. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug resistant ovarian cancer cells. Gynecol Oncol 2008;111(3):478-86.
37. Jackman D, Pao W, Engelman JA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28(2):357-60.
38. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119(10):3000-10.
39. Normanno N, Tejpar S, Morgillo F, De LA, Van CE, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6(9):519-27.
40. De Luca A, Normanno N. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. Curr Drug Targets 2010;11(7):851-64.
41. Lopez-Chavez A, Carter CA, Giaccone G. The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. Curr Opin Investig Drugs 2009;10(12):1305-14.
42. Weiss G, Nelson K, Edwards D, Boisvert S, Sima C. microRNA biomarkers associated with vandetanib, sunitinib, and/or erlotinib resistance. AACR/IASLC 2010.
43. Nelson K, Sima C, Edwards D, Weiss G. microRNA biomarkers associated with sunitinib resistance in non-small cell lung cancer. AACR 2010;abstract 3048.
44. Kovalchuk O, Filkowski J, Meservy J, Ilnyltskyy y, Tryndyak VP, Chekhun VF, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008;7(7):2152-9.
45. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan- CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 2009;284(39):26533- 46.
46. Sumaiyah R, Wen-Chien H, Dihua U. MiR-21 upregulation in breast cancer cells leads to PTEN loss and Herceptin resistance. AACR 2010;abstract 4033.
47. Sachdeva M, Wu H, Ru P, Hwang L, Trieu V, Mo YY. microRNA-101 promotes estrogen independent growth and confers tamoxifen resistance in ER positive breast cancer cells. AACR 2010;abstract 2104.
48. Lau L, Chan K, Khoo U. Identification of microRNAs associated with tamoxifen resistance in breast cancer. AACR 2010.
49. Zhou M, Zhao Y, Ding Y. Mir-125b confers the resistance of cancer cells to Taxol through suppression of Bak1. AACR 2010.
50. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T, et al. microRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009;8(5):1067-74.
51. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. microRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010; 411:11-2.
52. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010;127(8):1785-94.
53. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130(7):2113-29.
54. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. microRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010;42(8):1282-90.
55. Masri S, Liu Z, Phung S, Wang E, Yuan YC, Chen S. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat 2010;124:89-99.
56. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM. microRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 2009;276(22):6689-700.
57. Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, et al. MiR-148a attenuates paclitaxel-resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010;285(25):19076-84.
58. Kong W, He L, Coppola M. microRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010;285(23):17869-79.
59. Xin F, Li M, Balch C, Thomson M, Fan M, Liu Y, et al. Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 2009;25(4):430-4.
60. He FY, Chang JY, Kuo CC, Pan WY, Chen Lt WWH. microRNA expression patterns associated with resistance to platinum-based chemotherapy in human cancer cell lines. AACR 2010.
61. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. microRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008;283 (45):31079-86.
62. Garofalo M, Di LG, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16(6): 498-509.